Neuroprotective activity of a new erythropoietin formulation with increased penetration in the central nervous system

Table 1 Pharmacokinetics of rhEPO and rhNEPO in plasma and CSF after intravenous administration of a single dose of 500 µg of each protein in rats. The quantification of EPO derivatives were carried out by sandwich ELISA [1].

^a t_1/2α, distribution half-life; ^b t_1/2β, elimination half-life; ^c time to reach CSF after administration of EPO derivatives. ¹Distribution and elimination half-lives and their corresponding standard deviations were obtained using a bi-compartmental pharmacokinetic model. ² The t_CSF refers to the first time point in which EPO derivatives were detected in CSF, and for this reason standard deviations were not considered.

ISSN: 1753-6561